Finasteride Tablet, Film Coated
Product Images NDC 70518-3616

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 70518-3616). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Finasteride 5 mg film-coated tablets, containing 30 tablets per quantity. The label indicates the prescription status (RX ONLY) and includes NDC, manufacturing, and repackaging information by RemedyRepack Inc. The manufacturer is Aurobindo in India. Warnings note that the drug should not be used by women or children, with caution for pregnant women. Storage instructions and contact details for RemedyRepack are also present.*

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

A line graph titled 'Symptom Score in a Long-Term Efficacy and Safety Study' showing mean change from baseline ± 1 SE on the vertical axis and time points from Baseline to Year 4 on the horizontal axis. Two lines represent groups: Placebo (circles) and Finasteride (squares). Finasteride shows a greater decrease in symptom score over time compared to placebo. Sample sizes decrease each year from approximately 1438 at baseline to around 855-965 at Year 4.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

A line graph comparing the percent of patients undergoing surgery for BPH, including TURP, over a 48-month observation period between Finasteride and placebo groups. The graph shows cumulative events and number of patients at risk per year for both groups, with Finasteride consistently showing a lower percentage of surgeries compared to placebo.*

FDA Label Image

Figure3 (Finasteride Fig3)

A line graph titled 'Percent of Patients Developing Acute Urinary Retention (Spontaneous and Precipitated)' comparing patients taking Finasteride versus placebo over 48 months. The y-axis shows the percent of patients up to 15%, and the x-axis represents observation time in months. The graph includes cumulative event and at-risk patient counts for both groups at various time points.*

FDA Label Image

Figure4 (Finasteride Fig4)

A line graph titled 'Prostate Volume in a Long-Term Efficacy and Safety Study' showing mean percent change from baseline over a four-year period. Two lines represent changes for placebo and finasteride groups. The placebo line increases over time, while the finasteride line decreases and stabilizes below baseline. Participant counts for each group at baseline and yearly intervals are noted below the graph.*

FDA Label Image

Figure5 (Finasteride Fig5)

A line graph titled 'Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group' showing the percent with event on the vertical axis and years from randomization on the horizontal axis. The graph compares four groups: Placebo, Finasteride, Doxazosin, and Combination, with cumulative incidence increasing over approximately 5.5 years.*

FDA Label Image

Chemical Structure (Finasteride Str)

Chemical structure of finasteride, showing its steroidal framework with labeled functional groups including an amide and ketone group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.